Email: cspc@cspc.cn
Media
News Center
Feb. 19
2025
VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR SYS6005 WITH RADIANCE BIOPHARMA
Feb. 10
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
NEW INDICATION FOR ENYITAN® (OMALIZUMAB FOR INJECTION) OBTAINS MARKETING APPROVAL
Feb. 07
SYS6017 (HERPES ZOSTER mRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL
Jan. 20
REGORAFENIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Jan. 16
SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
